31 results about "Mupirocin" patented technology

The invention discloses a portable wound surface protection brace and an application method thereof, and belongs to the technical field of medical instruments. The brace is of a cylindrical structure, is made of EVA materials, has flexibility, non-toxic characteristics and good supporting performance and is externally wrapped with cotton cloth and provided with ventilation through holes, high-density cotton strips are fixed to the two ends of the inner wall to form a hollow structure, and the circumference of the outer wall can be adjusted through at least three sets of bandages with hook-and-loop fasteners. And an antibacterial coating is added, so that clinical application is expanded. During application, a wound surface is subjected to liquid extraction and hydrogen peroxide cleaning in the earlier stage and then covered with insulin mixed normal saline gauze, and the dressing is prevented from making contact with clothes in cooperation with a brace; and smearing mupirocin ointment in the later stage and performing infrared irradiation, and continuously using the brace to keep the wound dry and zero contact. The brace can be repeatedly used, can adapt to various wound types and patient body types, effectively solves the problems of wound adhesion and friction in traditional nursing, creates a high-oxygen healing environment, remarkably shortens wound healing time, relieves pain of patients and improves life quality, and has good clinical application and popularization value.

The invention relates to the field of high-molecular compounds, in particular to a mupirocin nano prodrug, a preparation method and application of the mupirocin nano prodrug to improvement of antibacterial activity in plasma, the general formula of the mupirocin nano prodrug is shown in the specification, X is O or NH, and n is equal to 1 or 6, the mupirocin nano prodrug can form regular and uniform spherical nanoparticles in a water phase in a nano precipitation mode, and the nano prodrug can be applied to preparation of antibacterial activity in plasma. According to the present invention, the mupirocin nano-prodrug has a certain antibacterial activity in vitro, the stability of mupirocin can be effectively improved by the self-assembly prodrug in the subsequent plasma antibacterial experiment, and the mupirocin nano-prodrug has the activity superior to the activity of the mupirocin active drug in the plasma antibacterial experiment.

The invention provides a material supplementing method for producing mupirocin through fermentation of pseudomonas fluorescens. The method specifically comprises the following steps: S1, preparing a material supplementing system: preparing material supplementing liquid, and adjusting the pressure difference between a material supplementing tank and a fermentation tank; s2, monitoring material supplementing trigger conditions: monitoring the dissolved oxygen content and the pH value in the fermentation tank in real time through a PLC control system; s3, executing a feeding program: starting a peristaltic pump to feed a feeding liquid in a quantitative feeding mode, and feeding ammonia water; and S4, dynamic feedback adjustment: controlling the flow of glucose supplement by adjusting the rotating speed of a peristaltic pump, controlling specific dissolved oxygen saturation in different fermentation stages by adjusting the ventilation quantity and the stirring rotating speed, and controlling specific pH values in different fermentation stages by supplementing ammonia water. According to the present invention, by designing the material supplementing liquid with the specific raw materials and the specific ratio, adopting the peristaltic pump to quantitatively supplement the material, and detecting and controlling the glucose content, the dissolved oxygen and the pH value during the fermentation process, the strain can grow and metabolize in the stable environment, the improvement of the mupirocin yield is promoted, the fermentation period is shortened, and the energy consumption is reduced.

The present invention discloses a fusion strain of Lactobacillus paracasei and Bifidobacterium adolescentis, as well as its preparation method and application, belonging to the field of strain breeding technology. A fusion strain of Lactobacillus paracasei and Bifidobacterium adolescentis was successfully prepared using the method provided by the present invention. The prepared fusion strain has a new morphology, a broadened carbon source utilization range, and significantly improved inhibitory effects on three pathogens. Furthermore, it is resistant to both vancomycin and mupirocin lithium salts. It also has good fermentation characteristics, with a pH of 4.05 and a titer of 114°T after 28 days of storage, and the viable cell count can still be maintained at 1×10 7 The protoplasts have a CFU / mL value of above 2260 mPa·s, a viscosity value of 37.462 g, a hardness of 37.462 g, and a consistency of 282.04 g·s, and can be used for the development and application of dairy products. The preparation method provided provides protoplasts with strong regeneration ability, high vitality, and high fusion rate, providing support for the selection of excellent lactic acid bacteria strains using protoplast fusion technology.

The invention discloses a nano antibacterial dressing and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. According to the nano-antibacterial dressing, mupirocin serves as an antibacterial component, chitosan, zein, tragacanth, sodium hyaluronate, sodium butyrate, a cross-linking agent, a humectant and other components are supplemented, and the nano-antibacterial dressing has efficient antibacterial performance, outstanding stability and simple preparation process and has important application value in wound healing and infection prevention and control.

The invention relates to the technical field of medicines, in particular to a pharmaceutical composition of mupirocin ointment and a preparation method of the pharmaceutical composition. The invention aims to solve the problem that the existing mupirocin ointment only pays attention to stability and neglects skin barrier repair, so that treatment and healing are disjointed. The composition comprises mupirocin, chitosan and the like, and is characterized in that a multiphase microstructure system is constructed, glyceryl monostearate provides hydrophobic protection for mupirocin, and lactic acid activates chitosan. The preparation method adopts three-stage temperature control synchronous homogeneous curing. The invention solves or at least alleviates the inherent defect that in the prior art, a mupirocin ointment preparation only focuses on the chemical stability of a medicine but neglects the biological requirement of skin barrier repair of a medication part, and provides a pharmaceutical composition of a mupirocin ointment and a preparation method thereof.

The application relates to a kind of dosing device for mupirocin ointment, relate to medical instrument technical field, it includes storage part, connecting part and extrusion part, storage part includes chute sleeve and storage box slidably arranged in chute sleeve, storage box is used to store mupirocin ointment in;Connecting part includes connecting ring, the two ends of connecting ring are respectively with the detachable link of storage part and extrusion part, the bottom of gauze can be contacted with mupirocin ointment in storage box when storage box vertically moves upward;Extrusion part includes fixed shell and extrusion assembly arranged in the inside of fixed shell, extrusion assembly is used to apply pressure to gauze, and gauze is adhered at wound site;Temperature adjusting assembly for heating or cooling extrusion assembly is arranged in extrusion part, and hot compress or cold compress of wound is realized.The application has the effect of evenly applying mupirocin ointment on wound site while alleviating patient's discomfort, improving the recovery efficiency of wound.

The invention relates to the technical field of medicines, and particularly discloses mupirocin ointment containing andrographolide and hydroxysafflor yellow A and a preparation method of the mupirocin ointment. The ointment comprises active ingredients of mupirocin, andrographolide and hydroxysafflor yellow A, and auxiliary materials of polyethylene glycol 3350 and polyethylene glycol 400. The mupirocin, the andrographolide and the hydroxysafflor yellow A are scientifically compounded, and different antibacterial mechanisms of the mupirocin, the andrographolide and the hydroxysafflor yellow A are utilized, so that a remarkable synergistic antibacterial effect is generated, drug-resistant bacteria can be effectively resisted, and generation of bacterial drug resistance is delayed. Meanwhile, by adding andrographolide and hydroxysafflor yellow A, the chemical stability of mupirocin in a polyethylene glycol matrix is accidentally improved, the validity period of the product is prolonged, and local microcirculation is improved. The invention further provides a preparation method of the ointment, the process is simple, and industrial production is easy.

The invention discloses mupirocin ointment easy to smear and good in stability and a preparation method of the mupirocin ointment, and belongs to the technical field of medicine preparation. The preparation method comprises the following steps: firstly, forming an alcohol-soluble supramolecular system by adopting citric acid and glycerol, and then adding mupirocin into the supramolecular system to form a mixed solution; uniformly mixing polyethylene glycol 3350, polyethylene glycol 400 and propylene glycol to obtain a matrix solution; finally, mixing, stirring and condensing the mixed solution and the matrix solution to obtain the mupirocin ointment. The mupirocin ointment prepared by the invention is easy to smear and good in stability, and has a wider application prospect.

The invention discloses a mupirocin ointment preparation device capable of accurately controlling temperature and slowly cooling, and relates to the technical field of ointment preparation. According to the scheme, the reaction kettle comprises a tank body with a jacket and further comprises a stirrer and a shaft body rotationally connected with the tank body, one end of the shaft body extends into the tank body, and a cooling flow channel is formed in the shaft body; the plurality of stirring blade units are distributed along the axial direction of the stirring shaft and are communicated with the cooling flow channel, and a cavity for a cooling medium to circulate is formed in each stirring blade unit; and the partition flow adjusting mechanism is arranged in the shaft body and is used for independently controlling on-off or flow of the cooling medium flowing to each stirring blade unit. Independent cooling loops are integrated in the stirring shaft and the blades, so that an internal cooling mode of directly exchanging heat from the inside of a material is realized, and an internal and external synergistic three-dimensional cooling network is formed by combining the internal cooling mode with external cooling of the jacket.

A Pharmaceutical composition for treating bacterial skin infections, burns and wounds is disclosed. It comprises an active ingredient, preferably Mupirocin, a biopolymer, preferably Chitosan, with molecular weight ranging from 250,000 Da to 600,000 Da, and a degree of deacetylation of not less than 80%, hydrolyzed Collagen, preferably of type I, with molecular weight ranging from 3 kDa to 6 kDa, and an ointment base comprising emulsifying agents, glycols and solubilizers. The invention has improved stability than the existing ointments, it heals skin and re-epithelializes faster than existing treatments thereby reducing hospitalisation period.

This invention provides a heating melting tank for producing mupirocin ointment, relating to the field of mupirocin ointment production technology. The heating melting tank for producing mupirocin ointment includes a tank body, a stirring shaft, stirring blades, a scraper, and a limiting assembly. The scraper is parallel to the stirring shaft and movably disposed on one side of the stirring shaft. The scraper has a first position and a second position. In the first position, the scraper abuts against the inner wall of the tank; in the second position, the scraper has a gap with the inner wall of the tank. The limiting assembly is disposed on the stirring shaft and connected to the scraper, used to limit and fix the scraper in the first and second positions. This invention has the effect of scraping off the mupirocin ointment adhering to the inner wall of the tank after discharge, thereby reducing waste.

The present application discloses an auxiliary extrusion device for mupirocin ointment, which relates to the technical field of medical devices. The device comprises a rotating smearing part, a fixed extruding part, a plurality of massage balls, and an smearing head. The fixed extruding part is cylindrical in shape and is used to place an aluminum tube of ointment inside. The rotating smearing part is coaxially arranged at one end of the fixed extruding part. All massage balls are movably connected to the end of the rotating smearing part away from the fixed extruding part. The massage balls are spaced around the central axis of the fixed extruding part. A first driving mechanism for driving the massage balls to rotate synchronously is provided in the rotating smearing part. The smearing head is rotatably connected to the rotating smearing part, and the rotation axis is coaxial with the axis of the fixed extruding part. An extrusion port is provided at the center of the smearing head for extruding the ointment. An auxiliary extrusion mechanism for extruding the ointment is provided in the fixed extruding part. The present application has the effect of facilitating the extrusion of ointment and alleviating the patient's pain.

The invention discloses a low-rate cooling control preparation device for mupirocin ointment, and relates to the technical field of ointment preparation. According to the scheme, the stirring device comprises a support and a tank body which is horizontally arranged on the support and provided with a jacket, the tank body comprises a movable section and fixed sections for rotationally sealing the two ends of the movable section, and the movable section can rotate around the axis of the movable section; comprising a fixed shaft, a stirring sleeve rotationally arranged outside the fixed shaft in a sleeving manner, and a plurality of blades mounted on the stirring sleeve; the driving mechanism is mounted on the bracket and is used for driving the movable section to rotate; and the synchronizing assembly is used for transmitting the rotary motion of the movable section to the stirring sleeve, so that the stirring sleeve and the movable section rotate in opposite directions. A strong two-way shear flow field is formed through autorotation of the tank body and reverse rotation of the stirrer in the tank body, so that the mixing efficiency is improved.

The invention relates to a dosing device for mupirocin ointment, and relates to the technical field of medical instruments, the dosing device comprises a storage part, a connecting part and an extrusion part, the storage part comprises a sliding groove sleeve and a storage box arranged in the sliding groove sleeve in a sliding mode, and the storage box is used for storing mupirocin ointment; the connecting part comprises a connecting ring, the two ends of the connecting ring are detachably connected with the storage part and the extrusion part respectively, gauze is contained in the connecting ring, and when the storage box vertically moves upwards, the bottom of the gauze can make contact with mupirocin ointment in the storage box; the extrusion part comprises a fixed shell and an extrusion assembly arranged in the fixed shell, and the extrusion assembly is used for applying pressure to the gauze and attaching the gauze to the wound; a temperature adjusting assembly used for heating or cooling the extrusion assembly is arranged in the extrusion part, and hot compress or cold compress on the wound is achieved. The application has the effects that the mupirocin ointment can be uniformly smeared on a wound while the discomfort of a patient is relieved, and the recovery efficiency of the wound is improved.

Mupirocin hydrogel system comprising chitosan and carboxymethyl chitosan nanoparticles for sustained drug release and improved wound healing.

The application belongs to the technical field of medicine, and discloses a kind of amidine compound and its preparation method and application in treating bacterial infection, specifically discloses a kind of amidine compound and its pharmaceutically acceptable salt and preparation method and application in treating bacterial infection as shown in the following general formula (I).The amidine compound of the application is used in the preparation of products for enhancing the activity of other antibiotics.The antibiotics include macrolide drugs, pleuromutilin drugs, quinolone drugs, rifamycin drugs, dihydrofolate reductase inhibitor drugs, oxazolidinone drugs, lincosamide drugs, capreomycin drugs, mupirocin drugs and fusidic acid drugs.

A bioactive nanofiber composition for combating biofilm-associated wound infections, comprising: Nanofibers formed from a polymer matrix comprising polyacrylonitrile (PAN) and polyvinyl alcohol (PVA); one or more therapeutic agents selected from fluticasone, mupirocin, ciprofloxacin and silver sulfadiazine; optionally in combination with at least one bioamplifier selected from nanodiamond, graphene oxide and rhamnose; the nanofiber matrix is ​​manufactured in such a way that it achieves the following: a uniform fiber diameter in the range of 100 to 500 nanometers, thereby improving the efficiency of drug encapsulation and release kinetics; a porosity between 70% and 90% to facilitate oxygen exchange and exudate absorption at the wound site; a mechanical tensile strength sufficient to ensure integrity during application and dressing changes; and the composition, through the synergistic combination of ciprofloxacin, mupirocin and silver sulfadiazine, exhibits a broad-spectrum antimicrobial effect against gram-positive and gram-negative biofilm-forming pathogens, thereby promoting sustained drug release and improved wound healing.

The invention discloses a mupirocin purification method, and belongs to the field of medical chemistry, according to the dissolution characteristic of mupirocin, by controlling the pH value, mupirocin fermentation liquor is firstly pretreated, then the fermentation liquor is filtered by using a ceramic membrane and transferred to a water phase, active ingredients of mupirocin in the fermentation liquor are enriched in a composite solvent, and the mupirocin purification method is obtained. The method comprises the following steps: washing a fermentation broth with saline water, adjusting the pH value of the solution, carrying out reverse extraction on mupirocin to a water phase, effectively removing impurities in the solution, improving the purity of mupirocin, removing part of organic matters with small polarity by using a composite solvent after reverse extraction, further improving the content of the effective component mupirocin, removing part of impurities with small polarity by using the composite solvent after reverse extraction, and further improving the purity of mupirocin. Through one-time crystallization, the product can meet the EP quality requirement.

The application belongs to the technical field of medicine, and discloses a kind of amidine compound and its preparation method and application in treating bacterial infection, specifically discloses a kind of amidine compound and its pharmaceutically acceptable salt and preparation method and application in treating bacterial infection as shown in the following general formula (I).The amidine compound of the application has the use in preparing the product for enhancing the activity of other antibiotics.The antibiotics include macrolide drugs, pleuromutilin drugs, quinolone drugs, rifamycin drugs, dihydrofolate reductase inhibitor drugs, oxazolidinone drugs, lincosamide drugs, capreomycin drugs, mupirocin drugs and fusidic acid drugs.

1. Name of the product of this design: Packaging kit (mupirocin ointment). 2. Purpose of this design product: used for product packaging. 3. The key design point of this product lies in the combination of pattern and color. 4. The image or photo that best illustrates the key design features: Kit 1 main view. 5. The design for which protection is sought includes color.

The invention relates to a preparation method and application of diselenide cross-linked mupirocin polyethylene glycol hydrogel, and belongs to the field of medical wound dressings for wound infection and promotion of wound healing. The preparation method comprises the following steps: reacting mupirocin with thionyl chloride to prepare acyl chloride, reacting with polyethylene glycol to prepare mupirocin grafted polyethylene glycol, reacting with gamma-selenobutyl ester under the action of 1, 5, 7-triazabicyclo [4.4. 0] dec-5-ene to prepare selenol, and oxidizing selenol by air to form diselenide crosslinking, thereby obtaining the diselenide crosslinked mupirocin polyethylene glycol hydrogel. The hydrogel disclosed by the invention has dual antibacterial properties of mupirocin and diselenide, can well absorb tissue waste liquid at a wound, keeps the periphery of the wound moist and free of hydrops, and promotes healing of the wound. The hydrogel does not adhere to new tissues and can be completely removed from a wound by wiping with medical 3% hydrogen peroxide, and secondary damage to the wound during stripping of a common medical wound dressing is effectively avoided.

The application belongs to the technical field of medicine, and discloses a kind of amidine compound and its preparation method and application in treating bacterial infection, specifically discloses a kind of amidine compound and its pharmaceutically acceptable salt and preparation method and application in treating bacterial infection as shown in the following general formula (I).The amidine compound of the application is used in the preparation of products for enhancing the activity of other antibiotics.The antibiotics include macrolide drugs, pleuromutilin drugs, quinolone drugs, rifamycin drugs, dihydrofolate reductase inhibitor drugs, oxazolidinone drugs, lincosamide drugs, capreomycin drugs, mupirocin drugs and fusidic acid drugs.

The present invention provides a method for preparing mupirocin ointment, comprising the steps of: mixing polyethylene glycol 3350, mupirocin, polyethylene glycol 400 and glycerol, heating the material to 80-90°C until melting and clarifying; cooling to 50-55°C; reducing the stirring speed to 18-22r / min and stirring, and homogenizing the material after the material cools to 45-50°C; increasing the stirring speed to 75-85 r / min and stirring for 55-65min, and then homogenizing; cooling the material to 40-45°C, stirring at 75-85 r / min for 280-320min, and homogenizing when the temperature reaches 38-42°C; regulating the stirring speed to 9-11 r / min, stirring for 110-130min at a temperature of 40-42°C, and obtaining the desired result after aging. The rheological properties of the mupirocin ointment prepared by the present invention can reach the same consistency as the original research fitting.

The invention provides a mupirocin ointment composition, a preparation method, application and related products, and belongs to the technical field of external ointment. The mupirocin ointment composition provided by the invention is prepared from the following components in parts by weight: 0.5 to 5.0 parts of mupirocin, 58 to 68 parts of liquid polyethylene glycol, 20 to 36 parts of solid polyethylene glycol, 1.07 to 5.07 parts of borneol, 0.30 to 0.82 part of quercetin, 0.41 to 0.93 part of S-acetyl-L-glutathione and 0.7 to 3.2 parts of urea. The mupirocin ointment composition can be used for preparing the mupirocin ointment, and compared with the prior art, the mupirocin ointment has higher transdermal speed, intradermal retention volume and drug utilization rate, and is high in storage stability and good in biocompatibility.

The embodiment of the invention provides a heating melting tank for producing mupirocin ointment, and relates to the technical field of mupirocin ointment production. The heating and melting tank for producing mupirocin ointment comprises a tank body, a stirring shaft, stirring blades, a scraping plate and a limiting assembly, the scraping plate is parallel to the stirring shaft and movably arranged on one side of the stirring shaft, the scraping plate is provided with a first position and a second position, and when the scraping plate is located at the first position, the scraping plate abuts against the inner wall of the tank body; when the scraper blade is located at the second position, a gap is formed between the scraper blade and the inner wall of the tank body; the limiting assembly is arranged on the stirring shaft and used for being connected with the scraping plate and used for limiting and fixing the scraping plate at the first position and the second position. The device has the effect of scraping off mupirocin ointment attached to the inner wall of the tank body after discharging of the melting tank so as to reduce waste.

The present application relates to a kind of mupirocin ointment and its preparation method, the ointment preparation specifically includes mupirocin, polyethylene glycol 400, polyethylene glycol 3350, cyclodextrin, the prepared preparation can solve mupirocin ointment stability problem, effectively control the period of validity within impurity increase, guarantee preparation quality and clinical curative effect, and the ointment preparation process is simple, easy to operate, suitable for industrialization scale production.

A method for extracting mupirocin. The main steps thereof comprise: resin adsorption, desorption and concentration, multi-step extraction, and dehydration and decoloration, wherein the multi-step extraction comprises at least one ester solvent extraction and at least one alkaline water extraction. The method is suitable for industrialization, the extraction recovery rate of mupirocin is 80% or more, and the purity of the mupirocin is 80% or more.

The present invention discloses a copper-containing hydrogel and its application in inhibiting bacterial infection. The copper-containing hydrogel is composed of the following: a copper ion compound, sodium alginate, and an auxiliary solvent. The antibacterial active ingredient is the copper ion compound. Through the antibacterial activity test of Staphylococcus aureus, it is determined that the copper ion compound has a strong bactericidal effect. When killing Staphylococcus aureus, its survival rate is less than 0.001%, and when killing methicillin-resistant Staphylococcus aureus (MRSA), its survival rate is less than 0.01%. Using a mouse model of Staphylococcus aureus-infected epidermal wound, we compared the copper-containing hydrogel with commonly used drugs erythromycin ointment and mupirocin ointment on the market and found that the copper-containing hydrogel has the strongest healing ability and wound surface clearance ability, and the copper ion compound does not belong to antibiotics and is not prone to drug resistance. Therefore, the copper-containing hydrogel has great application potential in wound infection.

The invention provides a gene engineering strain for producing mupirocin and a preparation method thereof. The rsmA is found to be a negative regulation gene for the first time, that is to say, the yield of mupirocin of pseudomonas fluorescens can be increased by knocking out the rsmA gene and reducing the expression of the rsmA gene or reducing the activity of rsmA protein. Furthermore, pseudomonas fluorescens is taken as a chassis strain, regulatory genes rsmA, rsmN and xylB genes are knocked out, and mupR genes are respectively integrated at corresponding positions, so that the strain for producing mupirocin is obtained; wherein rsmA is a negative regulation site, and rsmN and xylB are neutral sites, which belong to genome natural sites, are relatively stable and are not easy to lose in a passage process; meanwhile, the rsmA is knocked out and replaced with the mupR gene, the mupirocin yield can be increased through mupR gene expression, the negative regulation effect of the rsmA can be eliminated, and the mupirocin yield can be increased in a synergistic mode.